Tag: trademarks

FREMONT, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that San Diego Gas & Electric (SDG&E) has approved the IQ^® Meter Collar for behind-the-meter installations in its service territory. This milestone approval enables installers to deliver more streamlined home backup systems, with quicker installation, to customers in the SDG&E service territory.

Not for distribution to U.S. News wire services or dissemination in the U.S.

VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

WHEATON, Ill., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Innovator Capital Management, LLC (Innovator) announces that the net asset value (NAV) per share of the Innovator International Developed Power Buffer ETF™ (NYSE Arca: IAUG) for July 31, 2025, was adjusted by the amount indicated below on August 1, 2025. This adjustment is a result of an error in calculating IAUG’s NAV.

Leveraging the feasibility results from the NRCan-funded project, the project team is now aiming to complete the front-end engineering design for three facilities to convert wood waste feedstock into renewable diesel fuel

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.